The European drug authority recommends refusal of marketing authorization due to evidence gaps in quality and efficacy.

The drug failed to meet its primary endpoints in clinical trials, but subgroup analyses hinted at modest benefits.

Another study linked GLP-1 receptor agonist use with higher odds of developing nonarteritic anterior ischemic optic ...

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is one of the Stocks With Huge Catalysts on the Horizon. On July 25, Ionis ...

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) is one of the Stocks With Huge Catalysts on the Horizon. On July 25, KalVista ...

Sarepta will begin shipping its top-selling muscular dystrophy therapy, Elevidys, after the U.S. Food and Drug Administration ...

Swiss drugmaker Roche Holding plans to investigate whether an experimental medicine can delay or prevent Alzheimer’s disease ...

Bausch Health Companies Inc. (NYSE: BHC) (TSX: BHC), a global, diversified pharmaceutical company, and DURECT Corporation ...

Once touted as a potential powerhouse treatment for a variety of inflammatory conditions, Galapagos’ JAK inhibitor Jyseleca ...

European Medicines Agency recognizes potential of lead compound MP1032 in addressing a high unmet medical need in Duchenne Muscular Dystrophy (DMD)Designation is paving the way for safer long-term ...

The EU's medicines regulator said it would approve the treatment for a limited group of patients, citing concerns over side effects ...

Bausch Health is buying late-stage biopharmaceutical company Durect for about $63 million in cash up front, plus two possible additional payments totaling up to $350 million.